Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
Deniz TuralFatih SelçukbiricikÖmer Fatih ÖlmezAhmet Taner SümbülMustafa ErmanHasan Şenol CoşkunMehmet ArtaçSaadettin KılıçkapPublished in: International journal of clinical oncology (2021)
Our study demonstrated that clinical benefit from first-line chemotherapy was independent prognostic factors on OS in patients' use of ATZ as second-line treatment in metastatic bladder cancer. Furthermore, these findings are important for stratification factors for future immunotherapy study design in patients with bladder cancer who have progressed after first-line chemotherapy.
Keyphrases
- prognostic factors
- locally advanced
- end stage renal disease
- ejection fraction
- squamous cell carcinoma
- chronic kidney disease
- dna damage
- small cell lung cancer
- peritoneal dialysis
- radiation therapy
- rectal cancer
- chemotherapy induced
- current status
- patient reported outcomes
- oxidative stress
- patient reported
- replacement therapy